Two B or not two B; the question of bendamustine dosing in low grade lymphoma
A 1-day bendamustine regimen may offer comparable efficacy to the standard 2-day schedule, with a potentially more favorable toxicity profile and better convenience, especially in older or more vulnerable patient populations. These findings warrant further investigation in prospective randomized trials to establish optimal dosing strategies.
Authors
- Ágnes Fehér
- Virág Réka Szita
- E Földi
- Imre Bodó (ORCID: https://orcid.org/0000-0003-4170-8577)
- Gergely Szombath (ORCID: https://orcid.org/0000-0003-3680-0109)
- András Dávid Tóth (ORCID: https://orcid.org/0000-0003-2746-9370)
- Gergely Varga (ORCID: https://orcid.org/0000-0001-6875-056X)
- Ágnes Kárpáti
- Ilona Tárkányi (ORCID: https://orcid.org/0000-0002-4373-3947)
- Ádám Wiedemann
- Tamás Masszi (ORCID: https://orcid.org/0000-0003-2322-9863)
- Szabolcs Svorenj
- Zsolt Nagy (ORCID: https://orcid.org/0000-0001-9756-5427)
- Péter Farkas
- Laura Horváth
Institutions
- Semmelweis University (HU)
Publication Details
- Journal
- Pathology & Oncology Research
- Published
- 2025-09-25
- DOI
- https://doi.org/10.3389/pore.2025.1612195
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hungarian Scientific Research Fund
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal